Conde-Castro B, Blanco-Sixtos E, Cacho-González A, Jaime-Suárez BM, Martínez-Sánchez JL, Garza-Ramos P, Rivera-Rivera S, Sotelo-Martínez L

Language: Spanish
References: 12
Page: 188-201
PDF size: 723.15 Kb.

ABSTRACT

Background: among useful tools for management of patients with renal cancer, there are clinical criteria for prognosis and imaging methods to evaluate response to treatment. The most widely used imaging criteria include RECIST 1.1 (Response Evaluation Criteria In Solid Tumors), and more recently MASS (Morphology, Attenuation, Size, and Structure) to objectively evaluate response to treatment with targeted molecular therapy.
Objective: compare the usefulness of clinical criteria for prognosis of disease evolution and tomographic criteria to evaluate response to treatment.
Materials and methods: a retrospective study from January 2011 through December 2013 of data from patients with confirmed diagnosis of renal cancer, with baseline study and control by tomography at the Centro Médico Nacional Siglo XXI Cancer Hospital. Patients were categorized in accordance with the clinical criteria of Motzer and Heng to establish a prognosis and baseline and control tomograms were analyzed to evaluate in accordance with RECIST 1.1 and MASS criteria; also, an analysis of metastatic disease sites was included.
Results: data from 50 patients was analyzed, with mean tomographic monitoring of 298 days, with probability of non-progression of 87% at 223 days with no difference when using RECIST or MASS criteria. Motzer’s clinical criteria showed greater consistency in prognosis of disease progression and stability. The most common tumoral diseases were pulmonary and bone adenopathies.
Conclusions: the probability of non-progression was 87% at 223 days (p ‹ 0.05); there was no difference when using RECIST 1.1 or MASS evaluation criteria. Motzer’s classification showed greater consistency to prognosticate disease progression and stability compared with Heng’s classification.

REFERENCES

1. Nagaraj-Setty Holalkere, Daichi Hayashi, and Ali Guermaz. Renal Cell Carcinoma. En: Emilio Quaia, editor. Radiological Imaging of the Kidney. Berlin: Springer; 2011.

2. Jiménez R, Solares S, Martínez C. Cáncer Renal. Herrera G, Granados G. Manual de Oncología. Procedimientos medico quirúrgicos. 5ª edición. McGrawHill. México; 2013.

3. Young Jonathan, Margolis Daniel, Sauk Steven, et al. Clear Cell Renal Cell Carcinoma: Discrimination from Other Renal Cell Carcinoma Subtypes and Oncocytoma at Multiphasic Multidetector CT. Radiology 2012;267:444-453.

4. Bird VG, Kanagarajah P, Morillo G, et al. Differentiation of oncocytoma and renal cell carcinoma in small renal masses: the role of 4-phase computerized tomography. World J Urol 2011;29(6):787–792.

5. Andrew Dennis Smith, Shetal N. Shah, Brian I. Rini, Michael L. Lieber, Erick M. Remer Morphology, Attenuation, Size,and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in MetastaticRenal Cell Carcinoma on Antiangiogenic Targeted Therapy AJR 2010;194:1470–1478.

6. Lombardi G, Zustovich F, Donach M, Dall Palma M; Nicoletto O, Pastorelli D. An update on targeted therapy in metastasic renal cell carcinoma. Urol Oncol 2012;30(3):240-246.

7. Els L. van Persijn van Meerten RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010;20:1456–1467.

8. Figueiras RG, Padhani AR, Goh VJ, etl al. Novel oncologic drugs: what they do and how they affect images. Rario- Grapahics 2011;31(7):2059-2091.

9. Smith AD, Lieber ML, Shah SN. Assesing tumor response and detecting recurrence in metastasic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010;194:157-165.

10. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR 2007;189:360–370.

11. Daniel Y.C. Heng Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. J Clin Oncol 2009:27:140-186.

12. Motzer RJ et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.